Eli Lilly And Co (NYSE:LLY) – Equities research analysts at Cantor Fitzgerald reduced their FY2019 earnings per share (EPS) estimates for Eli Lilly And Co in a report issued on Wednesday, May 1st. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of $5.62 for the year, down from their previous forecast of $5.63. Cantor Fitzgerald currently has a “Buy” rating and a $143.00 target price on the stock.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.01. The firm had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 45.44%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.31 earnings per share.
NYSE:LLY opened at $117.86 on Friday. The stock has a market capitalization of $121.23 billion, a price-to-earnings ratio of 21.24, a PEG ratio of 2.22 and a beta of 0.27. Eli Lilly And Co has a 12 month low of $77.09 and a 12 month high of $132.13. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07.
In related news, SVP Stephen F. Fry sold 14,847 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $123.16, for a total transaction of $1,828,556.52. Following the completion of the sale, the senior vice president now directly owns 109,663 shares of the company’s stock, valued at $13,506,095.08. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $122.48, for a total transaction of $25,108,400.00. Following the sale, the insider now directly owns 117,641,684 shares of the company’s stock, valued at $14,408,753,456.32. The disclosure for this sale can be found here. Over the last three months, insiders have sold 863,382 shares of company stock valued at $108,785,182. 0.11% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of LLY. BDO Wealth Advisors LLC increased its stake in Eli Lilly And Co by 29.4% in the fourth quarter. BDO Wealth Advisors LLC now owns 2,229 shares of the company’s stock valued at $258,000 after purchasing an additional 506 shares in the last quarter. FDx Advisors Inc. increased its stake in Eli Lilly And Co by 48.3% in the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock valued at $2,257,000 after purchasing an additional 6,356 shares in the last quarter. Murphy Pohlad Asset Management LLC bought a new stake in Eli Lilly And Co in the fourth quarter valued at approximately $206,000. Princeton Global Asset Management LLC bought a new stake in Eli Lilly And Co in the fourth quarter valued at approximately $75,000. Finally, State of Alaska Department of Revenue increased its stake in Eli Lilly And Co by 3.3% in the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock valued at $23,660,000 after purchasing an additional 6,474 shares in the last quarter. 79.36% of the stock is owned by institutional investors and hedge funds.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: Understanding Average Daily Trade Volume
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.